Trial Profile
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Taselisib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Lung-MAP Sub-Study
- 07 Feb 2020 Status changed from discontinued to completed.
- 31 May 2019 Results of Lung-Map substudies (SWOG S1400B) published in the Journal of Thoracic Oncology
- 18 Oct 2017 Results of Lung-Map substudies (S1400A, B, C, D and E) presented at the 18th World Conference on Lung Cancer